ASCO 2020 | JAVELIN Bladder 100: practice-changing data

Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, outlines the findings from the JAVELIN Bladder 100 study (NCT02603432), a Phase III randomized trial of maintenance avelumab in advanced urothelial cancer patients who have not progressed with first-line platinum-based chemotherapy. Additionally, Dr Plimack highlights the practice-changing implications of these data. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).